More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...
Obecabtagene autoleucel showed effective outcomes in both younger and older adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with similar remission rates and chimeric antigen ...
Using CD22/CD19 CAR T-cell therapy followed by autologous stem cell transplant (ASCT) showed promising results in patients with Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results